Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Abstract Background Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid lis...
Huvudupphovsmän: | , , , , , , |
---|---|
Materialtyp: | Artikel |
Språk: | English |
Publicerad: |
BMC
2019-07-01
|
Serie: | BMC Public Health |
Ämnen: | |
Länkar: | http://link.springer.com/article/10.1186/s12889-019-7303-2 |